Blueprint Medicines has completed its acquisition of Lengo Therapeutics. The company develops therapeutics targeting driver mutations in oncology. The deal is worth $250 million. Blueprint will also pay an additional $215 million if LNG-451, a drug that could potentially treat non-small cell lung cancer patients with exon insertion mutations, reaches certain milestones.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept